Natco Pharma Ltd.

Natco Pharma is currently trading at Rs. 407.90, down by 60.45 points or 12.91% from its previous closing of Rs. 468.35 on the BSE.

The scrip opened at Rs. 425.00 and has touched a high and low of Rs. 438.80 and Rs. 401.00 respectively. So far 2,44,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 623.60 on 05-Jan-2016 and a 52 week low of Rs. 365.79 on 28-Apr-2015.

Last one week high and low of the scrip stood at Rs. 485.95 and Rs. 401.00 respectively. The current market cap of the company is Rs. 7,115.00 crore.

The promoters holding in the company stood at 51.31% while Institutions and Non-Institutions held 26.41% and 22.28% respectively.

The United States Food & Drug Administration (USFDA) has conducted inspection at two manufacturing facilities of Natco Pharma recently. The inspection was conducted at the Active Pharmaceutical Ingredients (API) manufacturing facility at Manali, near Chennai, and the Pharmaceutical Formulations facility at Kothur, near Hyderabad, during early February and March, 2016, respectively.

The company has received 483 observations for both facilities and believes them to be of minor in nature. The company has already sent response and compliance report for these observations and believes that there would be no adverse impact to its current or future pipeline products coming from these facilities.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.